Side-by-side comparison of AI visibility scores, market position, and capabilities
Waters Corporation (WAT) reported ~$2.97B revenue in FY2024. Premier maker of liquid chromatography instruments and mass spectrometers used in pharmaceutical quality control and research. HQ: Milford, MA.
Waters Corporation is the global leader in analytical instruments and detection technologies for the life science, pharmaceutical, and materials science industries, best known for its high-performance liquid chromatography (HPLC) systems, ultra-high performance liquid chromatography (UPLC) platforms, and mass spectrometry instruments used in drug discovery, quality control, and regulatory compliance. Founded in 1958 by Jim Waters, the company pioneered the commercialization of HPLC technology that is now the standard method for separating and analyzing chemical mixtures in pharmaceutical manufacturing.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.